期刊文献+

抗病毒药物的研究进展与发展趋势 被引量:4

在线阅读 下载PDF
导出
摘要 综述了近年来抗病毒药物的研究概况和将来的发展趋势 ,按药物不同的抗病毒作用特点进行分类 ,分别介绍了抗人类免疫缺陷病毒药物 ,抗巨细胞病毒药物 ,抗肝炎病毒药物 ,抗疱疹病毒药物 。
作者 蒋军
出处 《海峡药学》 2004年第6期1-3,共3页 Strait Pharmaceutical Journal
  • 相关文献

参考文献13

  • 1Anon.Videx C reduce GI side-effects[J].J Antimicrob Chemother,2000,45(4):417.
  • 2Drake SM.NNRTIs-a new class of drugs for HIV[J].J Antimicrob Chemother,2000,45(4):417.
  • 3马卫东.抗病毒药 Nelfinavir[J].国外医药(合成药.生化药.制剂分册),1999,20(2):86-87. 被引量:2
  • 4Aduma P,Connelly MC,Srinivas RV,et al.Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates[J].Mol Pharmacal,1995,47(4):816~822.
  • 5Sorbera LA,Castaner R Castaner J.Valganciclovir Hydrochloride anti-cytomegalovirus drug[J].Drugs Fut.2000,25(5):477.
  • 6Neri S,Pistone G,Saraceno B,et al,L-Carnitine decreases severity of patients with hepatitis C[J].Neuropsy-chobiology,2003,47(2):94~97.
  • 7Younossi ZM,Mullen KD,Hodnick S,et al Triple combination of interferon alpha-2b,ribavirin,and amantadine for treatment of chronic hepatitis C[J]J Clin Gastroenterol,2003,36(5):427~430.
  • 8Anon.Drug future.2002,27(7),702.
  • 9Pillay D,Mutimer D,Singhal S,et al.Management of herpes virus infection following transplantation.A report form the British Society for antimicrobial chemotherapy working party on antiviral therapy[J],J Antimicrob Chemother.2000,45(6):729.
  • 10冯秀梅,陈邦银,张汉萍.黄芪多糖硫酸酯的合成及其抗病毒活性研究[J].中国药科大学学报,2002,33(2):146-148. 被引量:24

二级参考文献16

  • 1田庚元,李寿桐,宋麦丽,郑民实,李文.牛膝多糖硫酸酯的合成及其抗病毒活性[J].药学学报,1995,30(2):107-111. 被引量:96
  • 2[1]BEUTNER KR, SPRUANCE SL, HOUGHAM AJ,et al.Treatment of genital warts with an immune-response modifier(imiquimod)[J].J Am Acad Dermatol,1998,38(2Pt 1):230-239.
  • 3[2]TYRING SK.Immune response modification:imiquimod[J].Aust J Dermatol,1998,39 Suppl 1:S11-S13.
  • 4[3]BEUTNER KR, FERENCZY A.Therapeutic approaches to genital warts[J].Am J Med, 1997,102(5A):28-37.
  • 5[4]IMBERTSON LM,BEAURLINE JM, COUTURE AM,et al.Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463[J].J Invest Dermatol,1998,110(5):734-739.
  • 6[5]TYRING SK, ARANY I,STANLEY MA,et al.A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod[J].J Infect Dis,1998,178(2):551-555.
  • 7[6]ARANY I, TYRING SK, STANLEY MA,et al.Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%[J].Antiviral Res, 1999,43(1):55-63.
  • 8[7]BOTTREL RL, YANG YL, LEVY DE,et al.The immune response modifier imiquimod requires STAT-1 for induction of interferon, interferon-stimulated genes, and interleukin-6[J].Antimicrob Agents Chemother, 1999,43(4):856-861.
  • 9[8]ARANY I, TYRING SK,BRYSK MM,et al.Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier(Imiquimod) in genital warts[J].Antimicrob Agents Chemoter,2000,44(7):1869-1873.
  • 10[9]EDWARDS L,FERENCZY A,ERON L,et al.Self-administered topical 5% imiquimod cream for external anogenital warts.HPV Study Group. Haman Popilloma Virus.[J].Arch Dermatol,1998,134(1):25-30.

共引文献42

同被引文献26

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部